Colossal's Open-Core Biobanking Strategy

The real monetization path is not selling access to the genomes, it is becoming the lab and recovery operator that every conservation program has to hire. Once genomic data is free, the scarce product becomes the physical workflow, finding hard to reach animals, collecting viable tissue, turning that tissue into cell lines, storing it safely for decades, and using it later for breeding, cloning, or genetic rescue.

• This is already how conservation biobanking works in practice. Field teams collect tissue, samples go to a cell culturing partner for processing or immediate cryopreservation, then material is archived and used to create reference genomes. That means revenue can attach to each operational step even if the finished genome is public.
  2 reviverestore 3 reviverestore 4 reviverestore
• The moat comes from assets that do not live in a database. A network that accumulates rare samples, permits, chain of custody, species specific protocols, and long term storage infrastructure is harder to copy than a public genome catalog. Existing preservation groups frame the same bottlenecks around collection, processing, sequencing, and cryopreservation capacity.
  1 sacra 2 reviverestore 3 reviverestore
• There is a clean analog in consumer genomics. 23andMe gives customers digital reports, but the paid product begins with sending in a saliva kit, lab processing the sample, generating genetic data, and increasingly selling higher value testing layers like exome sequencing. Colossal can apply the same open core logic to wildlife samples instead of human saliva.
  5 23andme 6 23andme 7 23andme

Over time this pushes Colossal toward a picks and shovels position for conservation genomics. If BioVault becomes the default place to bank tissue, build reference genomes, and reactivate preserved material for species recovery, the company can earn recurring service revenue while also owning the infrastructure layer that future restoration programs depend on.